New York – September 11, 2026 -- Monteverde & Associates PC has opened investigations into four pending mergers, questioning whether shareholders of Bio-Techne, Caesars Entertainment, Colony Bankcorp and Auddia are receiving fair value under the proposed deal terms.
Bio-Techne shareholders face $73.00-per-share cash buyout from Merck KGaA
Bio-Techne Corporation (NASDAQ: TECH) agreed to a sale to Merck KGaA under which shareholders are expected to receive $73.00 per share in cash. Monteverde & Associates is examining whether the price reflects fair value ahead of the deal's closing.
Caesars Entertainment deal includes $31.00 cash plus daily ticking fee
Caesars Entertainment, Inc. (NASDAQ: CZR) shareholders are slated to receive $31.00 per share in cash under its sale to Fertitta Gaming Holdco, LLC, plus a ticking consideration of $0.007150 per share for each calendar day elapsed after June 27, 2027. The firm is reviewing whether the structure adequately compensates investors for the extended timeline.
Colony Bankcorp merger offers First Reliance holders cash-or-stock choice
Colony Bankcorp, Inc. (NYSE: CBAN) is merging with First Reliance Bancshares, Inc., under terms giving First Reliance shareholders either $19.75 in cash or 0.94 of a Colony common share for each First Reliance share held. Monteverde & Associates is probing the fairness of both consideration options.
Auddia investors weigh one-for-one stock swap with McCarthy Finney
Auddia, Inc. (NASDAQ: AUUD) shareholders would receive one fully paid, nonassessable share of McCarthy Finney common stock for each Auddia share under the proposed merger. The exchange ratio is under scrutiny as part of the firm's broader review of pending 2026 transactions.